IceCure Medical Ltd.
corporate_fare Company Profile
IceCure Medical Ltd. (NASDAQ:ICCM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 48 items for ICCM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ICCM spans 6-K, F-3.
Recent high-impact activity:
- Q3 Loss Narrower Than Expected at $0.40/Share, But Revenue Slips 3.1%
- IceCure 9M 2026: Revenue Up 26% to $2.6M, U.S. Sales +83%, Cash Down to $8.2M
- IceCure Seeks Authority for Up to 40-for-1 Reverse Split to Hold Nasdaq Listing
- AMA Rejects Permanent CPT Code for IceCure's Breast Cryoablation — Reimbursement Stays Temporary
- IceCure Wins China Approval for ProSense Cryoablation System
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 56,133 shares in ICCM as of the October 30, 2026 settlement, a 33.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 36.1% of ICCM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ICCM, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
Warrant Exercise Price Reduction · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ICCM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.